HILLSTREAM BIOPHARMA INC (HILS) Stock Price & Overview

NASDAQ:HILS • US4327051011

0.2305 USD
+0.01 (+2.76%)
At close: Sep 22, 2023
0.2308 USD
+0 (+0.13%)
After Hours: 9/22/2023, 8:03:56 PM

The current stock price of HILS is 0.2305 USD. Today HILS is up by 2.76%. In the past month the price decreased by -4.75%. In the past year, price decreased by -70.5%.

HILS Key Statistics

52-Week Range0.1903 - 2.65
Current HILS stock price positioned within its 52-week range.
1-Month Range0.1903 - 0.295
Current HILS stock price positioned within its 1-month range.
Market Cap
3.876M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.73
Dividend Yield
N/A

HILS Stock Performance

Today
+2.76%
1 Week
-1.91%
1 Month
-4.75%
3 Months
-40.13%
Longer-term
6 Months -74.39%
1 Year -70.50%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

HILS Stock Chart

HILLSTREAM BIOPHARMA INC / HILS Daily stock chart

HILS Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to HILS. When comparing the yearly performance of all stocks, HILS is a bad performer in the overall market: 94.43% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
HILS Full Technical Analysis Report

HILS Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to HILS. While HILS seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
HILS Full Fundamental Analysis Report

HILS Earnings

Next Earnings DateNov 6, 2023
Last Earnings DateAug 11, 2023
PeriodQ2 / 2023
EPS Reported-$0.16
Revenue Reported
EPS Surprise 1.96%
Revenue Surprise %
HILS Earnings History

HILS Forecast & Estimates

6 analysts have analysed HILS and the average price target is 4.08 USD. This implies a price increase of 1670.07% is expected in the next year compared to the current price of 0.2305.


Analysts
Analysts43.33
Price Target4.08 (1670.07%)
EPS Next Y35.9%
Revenue Next YearN/A
HILS Forecast & Estimates

HILS Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

HILS Financial Highlights

Over the last trailing twelve months HILS reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS decreased by -160.68% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-8.92M
Industry RankSector Rank
PM (TTM) N/A
ROA N/A
ROE N/A
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-11.09%
Sales Q2Q%N/A
EPS 1Y (TTM)-160.68%
Revenue 1Y (TTM)N/A
HILS financials

HILS Ownership

Ownership
Inst Owners0.13%
Shares16.81M
Float12.67M
Ins Owners19.51%
Short Float %N/A
Short RatioN/A
HILS Ownership

HILS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC15.36401.392B
AMGN AMGEN INC16.57202.383B
GILD GILEAD SCIENCES INC16.52184.425B
VRTX VERTEX PHARMACEUTICALS INC25.29126.804B
REGN REGENERON PHARMACEUTICALS16.5981.619B
ALNY ALNYLAM PHARMACEUTICALS INC42.9742.754B
INSM INSMED INC N/A31.007B
NTRA NATERA INC N/A28.197B
BIIB BIOGEN INC11.8227.651B
UTHR UNITED THERAPEUTICS CORP18.2223.485B
MRNA MODERNA INC N/A21.714B
EXAS EXACT SCIENCES CORP340.3919.732B
RVMD REVOLUTION MEDICINES INC N/A19.591B

About HILS

Company Profile

HILS logo image Hillstream BioPharma, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) for drug resistant and devastating cancers. The company is headquartered in Bridgewater, New Jersey and currently employs 1 full-time employees. The company went IPO on 2022-01-12. The firm is engaged in developing therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for treatment-resistant cancers. The Company’s lead product candidate is HSB-1216, an IMCD modulator, targeting a variety of solid tumors. The drug HSB-1216 was found to reduce tumor in burden treatment resistant cancers, including triple negative breast cancer and epithelial carcinomas. The firm uses Quatramer, a tumor targeting platform, to enhance the uptake of HSB-1216 in the tumor microenvironment (TME). Its Trident Artificial Intelligence, an artificial intelligence precision medicine platform used to identify biomarkers in clinical programs to target specific patient segments. The Company’s pipeline includes HSB-1216, HSB-888, HSB-510 and HSB-114. HSB-1216 pipeline is a novel inducer of iron-mediated cell death.

Company Info

IPO: 2022-01-12

HILLSTREAM BIOPHARMA INC

1200 Route 22 East, Suite 2000

Bridgewater NEW JERSEY US

Employees: 1

HILS Company Website

Phone: 19089553140.0

HILLSTREAM BIOPHARMA INC / HILS FAQ

What does HILLSTREAM BIOPHARMA INC do?

Hillstream BioPharma, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) for drug resistant and devastating cancers. The company is headquartered in Bridgewater, New Jersey and currently employs 1 full-time employees. The company went IPO on 2022-01-12. The firm is engaged in developing therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for treatment-resistant cancers. The Company’s lead product candidate is HSB-1216, an IMCD modulator, targeting a variety of solid tumors. The drug HSB-1216 was found to reduce tumor in burden treatment resistant cancers, including triple negative breast cancer and epithelial carcinomas. The firm uses Quatramer, a tumor targeting platform, to enhance the uptake of HSB-1216 in the tumor microenvironment (TME). Its Trident Artificial Intelligence, an artificial intelligence precision medicine platform used to identify biomarkers in clinical programs to target specific patient segments. The Company’s pipeline includes HSB-1216, HSB-888, HSB-510 and HSB-114. HSB-1216 pipeline is a novel inducer of iron-mediated cell death.


Can you provide the latest stock price for HILLSTREAM BIOPHARMA INC?

The current stock price of HILS is 0.2305 USD. The price increased by 2.76% in the last trading session.


Does HILS stock pay dividends?

HILS does not pay a dividend.


What is the ChartMill rating of HILLSTREAM BIOPHARMA INC stock?

HILS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Can you provide the market cap for HILLSTREAM BIOPHARMA INC?

HILLSTREAM BIOPHARMA INC (HILS) has a market capitalization of 3.88M USD. This makes HILS a Nano Cap stock.


When does HILLSTREAM BIOPHARMA INC (HILS) report earnings?

HILLSTREAM BIOPHARMA INC (HILS) will report earnings on 2023-11-06.